1. Novel antibody-drug conjugates based on DXd-ADC technology.
- Author
-
Chen, Rong, Ren, Zhiwen, Bai, Lan, Hu, Xuefang, Chen, Yuchen, Ye, Qiang, Hu, Yuan, and Shi, Jianyou
- Subjects
- *
ANTIBODY-drug conjugates , *SMALL molecules , *CELL cycle , *CYTOTOXINS , *DNA damage - Abstract
[Display omitted] In recent years, antibody-drug conjugate (ADC) technology, which uses monoclonal antibodies (mAbs) to specifically deliver effective cytotoxic payloads to tumor cells, has become a promising method of tumor targeted therapy. ADCs are a powerful class of biopharmaceuticals that link antibodies targeting specific antigens and small molecule drugs with potent cytotoxicity via a linker, thus enabling selective destruction of cancer cells while minimizing systemic toxicity. DXd is a topoisomerase I inhibitor that induces DNA damage leading to cell cycle arrest, making it an option for ADC payloads. The DXd-ADC technology, developed by Daiichi Sankyo, is a cutting-edge platform that produces a new generation of ADCs with improved therapeutic metrics and has shown significant therapeutic potential in various types of cancer. This review provides a comprehensive assessment of drugs developed with DXd-ADC technology, with a focus on mechanisms of action, pharmacokinetics studies, preclinical data, and clinical outcomes for DS-8201a, U3-1402, DS-1062a, DS-7300a, DS-6157a, and DS-6000a. By integrating existing data, we aim to provide valuable insights into the current therapeutic status and future prospects of these novel agents. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF